This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 02
  • /
  • NICE in draft guidance does not recommend the comb...

NICE in draft guidance does not recommend the combination of Keytruda + Inlyta to treat renal cell carcinoma. Merck Inc.+ Pfizer

Read time: 1 mins
Published:15th Feb 2020
The National Institute for Health and Care Excellence (NICE) has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used in combination with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma . The rejection comes despite notable results from the KEYNOTE-426 study, released in 2019, which showed that Keytruda/Inlyta was associated with improved overall survival (hazard ratio 0.53; 95% CI of 0.38 to 0.74; P = 0.00005) and improved progression-free survival (hazard ratio 0.69; 95% CI of 0.57 to 0.84; p = 0.00014) compared with Pfizer’s Sutent (sunitinib) monotherapy. However NICE found that there was uncertainty around the long-term benefit. NICE also cited inadequate clinical and cost-effectiveness as reasons for not recommending the combination.
Condition: Renal Cell Carcinoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights